Researchers confirm that polyp removal has long-term benefits.
Most people think of colonoscopies as screening tests (and dread the thought of them): however, colonoscopic polyp removal also is a very effective cancer prevention measure. Researchers conducting the National Polyp Study (NPS) evaluated the long-term effect of colonoscopic polypectomy and found that removal of adenomatous polyps prevents deaths from colon cancer.
The researchers prospectively studied all patients referred for an initial colonoscopy between 1980 and 1990 at NPS clinical centers located throughout the U.S. and were found to have polyps (adenomas and nonadenomas). The National Death Index was used to determine the cause of death. Deaths from colorectal cancer among patients with adenomas that were removed were compared with the expected incidence-based mortality from colorectal cancer in the general population, as estimated from the Surveillance Epidemiology and End Results (SEER) Program, and with the observed death rates from colorectal cancer among patients with nonadenomatous polyps (control group).
Of the 2,602 people who had adenomas removed, 1,246 had died from any cause and 12 had died from colorectal cancer. The researchers calculated the number of expected deaths from colorectal cancer in the general population (25.4 expected deaths) and concluded that there is a 53% reduction in the death rate when polyps are removed during colonoscopy. Although colonoscopy is one of the more unpleasant screening tests available, the National Polyp Study has generated important data to support its utilization.
Zauber AG, Winawer, SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366 (8): 687-696.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.